HZRM Haemophilie-Zentrum Rhein Main GmbH
- Address
- lock Available on a paid plan
Hereditary Angioedema Research
At HZRM Haemophilie-Zentrum Rhein Main GmbH, much of the clinical trial activity focuses on immune system diseases and hereditary angioedema. These studies are designed to improve both attack treatment and preventive care for people living with this rare swelling disorder.
- Testing new options for treating acute HAE attacks and easing symptoms faster
- Evaluating long-term preventive therapies for hereditary angioedema in adolescents, adults, and children
- Assessing safety, tolerability, and overall effectiveness of emerging angioedema treatments
Research at this site includes both on-demand and prophylactic approaches, with a strong emphasis on making HAE care safer, more reliable, and better suited to different age groups.
Haemophilia A Studies
The site also conducts trials in hemic and lymphatic diseases, especially Haemophilia A and Haemophilia A with inhibitors. These studies aim to support better bleeding prevention and improve treatment outcomes for patients with this inherited bleeding disorder.
- Studying long-term preventive treatment to reduce bleeding episodes in Haemophilia A
- Exploring treatment strategies for patients with FVIII inhibitors
- Evaluating joint health and real-world effectiveness of newer bleeding-prevention therapies
This research helps clarify how newer therapies may improve daily disease control, especially for patients who need ongoing protection against bleeds.
Pediatric and Family-Focused Rare Disease Trials
The Hamophilie Zentrum Rhein Main participates in studies that include children, adolescents, and infants, reflecting a broader focus on congenital and hereditary diseases. These trials are important for understanding how rare disease treatments perform across different age groups.
- Assessing safety and treatment response in pediatric hereditary angioedema
- Investigating preventive therapy options for young children with HAE
- Studying early-life treatment approaches in Haemophilia A, including patients with and without inhibitors
By including younger patients, the research supports more age-appropriate care and helps expand treatment choices for rare inherited conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Pharvaris Netherlands B.V.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pharvaris Netherlands B.V.4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HZRM Haemophilie-Zentrum Rhein Main GmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | CSL Behring LLC | Phase III | Not Recruiting | May 2024 | Oct 2025 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucrictibant | 4 | Unknown | 2022-10-10 | 2025-03-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.